Áttétes emlőrák: vizsgálatok itt: Kína
224 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- No phaseTaking peopleCurrent Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 450
- Run by
- SciClone Pharmaceuticals
See details and how to joinNCT06548919 - 2. fázisCsak meghívásosT-DM1 Combined With CDK4/6 Inhibitor Ribociclib
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 40
- Run by
- Zheng Yabing
See details and how to joinNCT06481956 - 3. fázisTaking peopleDP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 442
- Run by
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT06313086 - 2. fázisTaking peopleAdebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 82
- Run by
- Tongji Hospital
See details and how to joinNCT06149130 - 2. fázisNot yet taking people in KínaA Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
- Where
- Harbin
- Életkor
- 18 év and over
- People
- 80
- Run by
- CSPC Ouyi Pharmaceutical Co., Ltd.
See details and how to joinNCT06354114 - 1/2. fázisTaking peopleA Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
- Where
- Chongqing, Harbin
- Életkor
- 18 év to 75 év
- People
- 154
- Run by
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT06202261 - 3. fázisTaking peopleDisitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 312
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06278870 - 2. fázisTaking peopleEfficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 265
- Run by
- Fudan University
See details and how to joinNCT05949541 - 4. fázisNot yet taking people in KínaTrastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 51
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06245824 - 2. fázisTaking peoplePARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 200
- Run by
- Fudan University
See details and how to joinNCT05759546 - 4. fázisNot yet taking people in KínaClinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- Where
- Changsha, Hangzhou, Jiaxin, Lishui, Nantong, Shanghai, Shijiazhuang, Taizhou, Yangzhou, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 384
- Run by
- Fudan University
See details and how to joinNCT05860907 - 2. fázisTaking peopleChidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 102
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT05983107 - 2. fázisNot yet taking people in KínaStudy of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 178
- Run by
- Shuangyue Liu
See details and how to joinNCT05979220 - 3. fázisTaking peopleUtidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
- Where
- Guangzhou, Hunan
- Életkor
- 18 év and over
- People
- 349
- Run by
- Sun Yat-sen University
See details and how to joinNCT05430399 - 3. fázisTaking peopleDisitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
- Where
- Guangzhou, Qionghai, Shantou
- Életkor
- 18 év to 70 év
- People
- 288
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT05904964 - No phaseTaking peopleCDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 172
- Run by
- RenJi Hospital
See details and how to joinNCT05795335 - No phaseTaking peopleEfficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 100
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT05856383 - 3. fázisTaking peopleA Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Jining, Kunming, Liaocheng, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shangrao, Shenyang, Taiyuan, Tianjin, Ürümqi, Wenzhou, Wuhan, Xiamen, Xi'an, Xingtai, Yingchuan, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 350
- Run by
- Genor Biopharma Co., Ltd.
See details and how to joinNCT05851014 - 3. fázisTaking peopleFulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Where
- Changsha, Guangzhou, Nanning, Shantou, Shenzhen, Zhangjiang, Zhuhai
- Életkor
- 18 év to 75 év
- People
- 210
- Run by
- Herui Yao
See details and how to joinNCT04263298 - Korai 1. fázisNot yet taking people in KínaStudy on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer
- Where
- Qingdao
- Életkor
- 18 év to 75 év
- People
- 10
- Run by
- The Affiliated Hospital of Qingdao University
See details and how to joinNCT05505812 - 2. fázisNot yet taking people in KínaThe Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 53
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT05431504 - 3. fázisNot yet taking people in KínaUtidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 512
- Run by
- Sun Yat-sen University
See details and how to joinNCT05172518 - 3. fázisNot yet taking people in KínaInetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
- Where
- Beijing
- Életkor
- 18 év to 85 év
- People
- 270
- Run by
- Peking Union Medical College
See details and how to joinNCT04736589 - 3. fázisTaking peopleFulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
- Where
- Guangzhou
- Életkor
- 18 év to 80 év
- People
- 516
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT04646759